{"protocolSection": {"identificationModule": {"nctId": "NCT03510663", "orgStudyIdInfo": {"id": "263-102-00005"}, "secondaryIdInfos": [{"id": "JapicCTI-183934", "type": "OTHER", "domain": "Japic"}], "organization": {"fullName": "Otsuka Pharmaceutical Co., Ltd.", "class": "INDUSTRY"}, "briefTitle": "Phase I Study of OPC-61815", "officialTitle": "A Single-center, Randomized, Double-blind (for OPC-61815 and Placebo), Placebo- and Moxifloxacin Positive-controlled, 4-Period Crossover Trial to Evaluate the Effect of Single Intravenous Administration of OPC-61815 at 16 and 32 mg on QT/QTc Interval in Healthy Male Subjects"}, "statusModule": {"statusVerifiedDate": "2021-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-05-08", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-07-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-07-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-04-18", "studyFirstSubmitQcDate": "2018-04-26", "studyFirstPostDateStruct": {"date": "2018-04-27", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2021-03-12", "resultsFirstSubmitQcDate": "2021-04-13", "resultsFirstPostDateStruct": {"date": "2021-05-10", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-04-13", "lastUpdatePostDateStruct": {"date": "2021-05-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Otsuka Pharmaceutical Co., Ltd.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "To investigate the effects of intravenous administration of OPC-61815 at 16 and 32 mg on QT/QTc interval in healthy male subjects"}, "conditionsModule": {"conditions": ["Congestive Heart Failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 48, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "OPC-61815 16mg", "type": "EXPERIMENTAL", "description": "OPC-61815 16mg will be intravenously administered once a week.", "interventionNames": ["Drug: OPC-61815 16mg"]}, {"label": "OPC-61815 32mg", "type": "EXPERIMENTAL", "description": "OPC-61815 32mg will be intravenously administered once a week.", "interventionNames": ["Drug: OPC-61815 32mg"]}, {"label": "Moxifloxacin", "type": "ACTIVE_COMPARATOR", "description": "400mg tablet will be administrated once a week.", "interventionNames": ["Drug: Moxifloxacin"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo will be intravenously administered once a week.", "interventionNames": ["Drug: Placebos"]}], "interventions": [{"type": "DRUG", "name": "OPC-61815 16mg", "description": "OPC-61815 16mg will be intravenously administered once a week.", "armGroupLabels": ["OPC-61815 16mg"]}, {"type": "DRUG", "name": "OPC-61815 32mg", "description": "OPC-61815 32mg will be intravenously administered once a week.", "armGroupLabels": ["OPC-61815 32mg"]}, {"type": "DRUG", "name": "Moxifloxacin", "description": "400mg tablet will be administrated once a week.", "armGroupLabels": ["Moxifloxacin"]}, {"type": "DRUG", "name": "Placebos", "description": "Placebo will be intravenously administered once a week.", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Time-matched Difference Between the OPC-61815/Moxifloxacin and Placebo Data in Change From Baseline for QTcF in 12-lead Holter Electrocardiogram (ECG)", "description": "For each OPC-61815 dose, the upper limit of the confidence interval (CI) for the time-matched difference in the least squares (LS) mean for the change in QT corrected for heart rate by Fridericia's formula (QTcF) from baseline compared to the placebo data was evaluated to determine if it was lower than 10 msec at all postdose time points. Using a linear mixed effect model with baseline QTcF in each treatment period as a covariate, treatment, sequence, treatment period, time point, and interaction between treatment and time point as fixed effects, and subject as a random effect, point estimates and CIs for the time-matched difference in the LS mean for the change in QTcF from baseline compared to the placebo data were calculated.", "timeFrame": "Baseline, 1h, 1.5h, 2h, 3h, 4h, 6h, 12h, 24h after dosing"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Body mass index (BMI) \\[body weight in kg / (height in m)2\\] of at least 18.5 kg/m2 and less than 25.0 kg/m2 as a result of at the screening examination\n* Judged by the investigator or subinvestigator to be capable of providing written informed consent prior to start of any trial-related procedures and capable of complying with the procedures for this trial\n\nExclusion Criteria:\n\n* Subjects with a medical history of convulsive disorder, long QT syndrome (including family history), syncope during swimming, or any other type of syncope or cryptogenic loss of consciousness\n* Subjects with a serum electrolyte abnormality (hypokalemia, hypomagnesemia, hypocalcemia, etc)\n* Subjects with a family history of sudden death", "healthyVolunteers": true, "sex": "MALE", "minimumAge": "20 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Osamu Sato", "affiliation": "Otsuka Pharmaceutical Co., Ltd.", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Kyusyu Region", "city": "Fukuoka", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Sequence 1 (ABDC)", "description": "Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.\n\nA: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin\n\nOPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of investigational medicinal product (IMP) administration in a treatment period and the next treatment period."}, {"id": "FG001", "title": "Sequence 2 (DACB)", "description": "Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.\n\nA: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin\n\nOPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period."}, {"id": "FG002", "title": "Sequence 3 (BCAD)", "description": "Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.\n\nA: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin\n\nOPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period."}, {"id": "FG003", "title": "Sequence 4 (CDBA)", "description": "Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.\n\nA: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin\n\nOPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period."}, {"id": "FG004", "title": "Sequence 5 (ABCD)", "description": "Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.\n\nA: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin\n\nOPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period."}, {"id": "FG005", "title": "Sequence 6 (CADB)", "description": "Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.\n\nA: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin\n\nOPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period."}, {"id": "FG006", "title": "Sequence 7 (BDAC)", "description": "Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.\n\nA: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin\n\nOPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period."}, {"id": "FG007", "title": "Sequence 8 (DCBA)", "description": "Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.\n\nA: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin\n\nOPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "6"}, {"groupId": "FG006", "numSubjects": "6"}, {"groupId": "FG007", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "6"}, {"groupId": "FG004", "numSubjects": "6"}, {"groupId": "FG005", "numSubjects": "6"}, {"groupId": "FG006", "numSubjects": "6"}, {"groupId": "FG007", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}, {"groupId": "FG006", "numSubjects": "0"}, {"groupId": "FG007", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sequence 1 (ABDC)", "description": "Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.\n\nA: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin\n\nOPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of investigational medicinal product (IMP) administration in a treatment period and the next treatment period."}, {"id": "BG001", "title": "Sequence 2 (DACB)", "description": "Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.\n\nA: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin\n\nOPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period."}, {"id": "BG002", "title": "Sequence 3 (BCAD)", "description": "Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.\n\nA: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin\n\nOPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period."}, {"id": "BG003", "title": "Sequence 4 (CDBA)", "description": "Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.\n\nA: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin\n\nOPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period."}, {"id": "BG004", "title": "Sequence 5 (ABCD)", "description": "Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.\n\nA: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin\n\nOPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period."}, {"id": "BG005", "title": "Sequence 6 (CADB)", "description": "Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.\n\nA: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin\n\nOPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period."}, {"id": "BG006", "title": "Sequence 7 (BDAC)", "description": "Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.\n\nA: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin\n\nOPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period."}, {"id": "BG007", "title": "Sequence 8 (DCBA)", "description": "Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.\n\nA: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin\n\nOPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period."}, {"id": "BG008", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "6"}, {"groupId": "BG005", "value": "6"}, {"groupId": "BG006", "value": "6"}, {"groupId": "BG007", "value": "6"}, {"groupId": "BG008", "value": "48"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.7", "spread": "11.4"}, {"groupId": "BG001", "value": "27.3", "spread": "7.4"}, {"groupId": "BG002", "value": "30.2", "spread": "7.7"}, {"groupId": "BG003", "value": "26.5", "spread": "9.1"}, {"groupId": "BG004", "value": "28.3", "spread": "8.4"}, {"groupId": "BG005", "value": "30.3", "spread": "4.4"}, {"groupId": "BG006", "value": "27.5", "spread": "4.1"}, {"groupId": "BG007", "value": "26.2", "spread": "6.4"}, {"groupId": "BG008", "value": "28.5", "spread": "7.3"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}, {"groupId": "BG006", "value": "0"}, {"groupId": "BG007", "value": "0"}, {"groupId": "BG008", "value": "0"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "6"}, {"groupId": "BG005", "value": "6"}, {"groupId": "BG006", "value": "6"}, {"groupId": "BG007", "value": "6"}, {"groupId": "BG008", "value": "48"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Japanese", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "6"}, {"groupId": "BG005", "value": "6"}, {"groupId": "BG006", "value": "6"}, {"groupId": "BG007", "value": "6"}, {"groupId": "BG008", "value": "48"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Japan", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "6"}, {"groupId": "BG005", "value": "6"}, {"groupId": "BG006", "value": "6"}, {"groupId": "BG007", "value": "6"}, {"groupId": "BG008", "value": "48"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Time-matched Difference Between the OPC-61815/Moxifloxacin and Placebo Data in Change From Baseline for QTcF in 12-lead Holter Electrocardiogram (ECG)", "description": "For each OPC-61815 dose, the upper limit of the confidence interval (CI) for the time-matched difference in the least squares (LS) mean for the change in QT corrected for heart rate by Fridericia's formula (QTcF) from baseline compared to the placebo data was evaluated to determine if it was lower than 10 msec at all postdose time points. Using a linear mixed effect model with baseline QTcF in each treatment period as a covariate, treatment, sequence, treatment period, time point, and interaction between treatment and time point as fixed effects, and subject as a random effect, point estimates and CIs for the time-matched difference in the LS mean for the change in QTcF from baseline compared to the placebo data were calculated.", "populationDescription": "Central tendency analysis for OPC-61815 was performed for subjects in the Pharmacodynamic Analysis Set who appropriately completed all IMP treatments and for whom predose and postdose QT data are available for all 4 treatment periods. One subject was excluded from the central tendency analysis due to lack of QT data following OPC-61815 16 mg, OPC-61815 32 mg, and placebo administration.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "msec", "timeFrame": "Baseline, 1h, 1.5h, 2h, 3h, 4h, 6h, 12h, 24h after dosing", "groups": [{"id": "OG000", "title": "OPC-61815 16 mg", "description": "OPC-61815 16 mg was intravenously administered once a week."}, {"id": "OG001", "title": "OPC-61815 32 mg", "description": "OPC-61815 32 mg was intravenously administered once a week."}, {"id": "OG002", "title": "Moxifloxacin", "description": "400 mg tablet was orally administrated once a week."}, {"id": "OG003", "title": "Placebo", "description": "Placebo was intravenously administered once a week."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "48"}, {"groupId": "OG002", "value": "48"}, {"groupId": "OG003", "value": "48"}]}], "classes": [{"title": "1 hour postdose", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.9", "spread": "1.1"}, {"groupId": "OG001", "value": "0.0", "spread": "1.1"}, {"groupId": "OG002", "value": "9.9", "spread": "1.1"}, {"groupId": "OG003", "value": "-0.9", "spread": "1.1"}]}]}, {"title": "1.5 hours postdose", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "spread": "1.1"}, {"groupId": "OG001", "value": "1.3", "spread": "1.1"}, {"groupId": "OG002", "value": "9.5", "spread": "1.1"}, {"groupId": "OG003", "value": "-0.7", "spread": "1.1"}]}]}, {"title": "2 hours postdose", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.7", "spread": "1.1"}, {"groupId": "OG001", "value": "0.4", "spread": "1.1"}, {"groupId": "OG002", "value": "10.8", "spread": "1.1"}, {"groupId": "OG003", "value": "-0.4", "spread": "1.1"}]}]}, {"title": "3 hours postdose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "1.1"}, {"groupId": "OG001", "value": "-2.2", "spread": "1.1"}, {"groupId": "OG002", "value": "10.9", "spread": "1.1"}, {"groupId": "OG003", "value": "-0.6", "spread": "1.1"}]}]}, {"title": "4 hours postdose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.6", "spread": "1.1"}, {"groupId": "OG001", "value": "-2.2", "spread": "1.1"}, {"groupId": "OG002", "value": "11.1", "spread": "1.1"}, {"groupId": "OG003", "value": "1.5", "spread": "1.1"}]}]}, {"title": "6 hours postdose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.9", "spread": "1.1"}, {"groupId": "OG001", "value": "-10.8", "spread": "1.1"}, {"groupId": "OG002", "value": "1.9", "spread": "1.1"}, {"groupId": "OG003", "value": "-8.5", "spread": "1.1"}]}]}, {"title": "12 hours postdose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.6", "spread": "1.1"}, {"groupId": "OG001", "value": "-9.8", "spread": "1.1"}, {"groupId": "OG002", "value": "2.6", "spread": "1.1"}, {"groupId": "OG003", "value": "-4.7", "spread": "1.1"}]}]}, {"title": "24 hours postdose", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.6", "spread": "1.1"}, {"groupId": "OG001", "value": "-2.8", "spread": "1.1"}, {"groupId": "OG002", "value": "4.3", "spread": "1.1"}, {"groupId": "OG003", "value": "-2.7", "spread": "1.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "groupDescription": "1 hour postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "1.8", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.4", "ciUpperLimit": "4.1"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "1.5 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "2.7", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.4", "ciUpperLimit": "4.9"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "2 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "2.1", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.1", "ciUpperLimit": "4.4"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "3 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "-0.5", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.8", "ciUpperLimit": "1.7"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "4 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "-4.1", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.3", "ciUpperLimit": "-1.8"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "6 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "-3.5", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.7", "ciUpperLimit": "-1.2"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "12 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "-4.9", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.1", "ciUpperLimit": "-2.6"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "24 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "-0.9", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.1", "ciUpperLimit": "1.4"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "1 hour postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "0.9", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.4", "ciUpperLimit": "3.1"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "1.5 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "2.0", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.2", "ciUpperLimit": "4.2"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "2 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "0.9", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.4", "ciUpperLimit": "3.1"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "3 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "-1.6", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.8", "ciUpperLimit": "0.7"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "4 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "-3.7", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.9", "ciUpperLimit": "-1.5"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "6 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "-2.3", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.6", "ciUpperLimit": "-0.1"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "12 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "-5.1", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.3", "ciUpperLimit": "-2.8"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "24 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "-0.2", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.4", "ciUpperLimit": "2.1"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "1 hour postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "10.8", "ciPctValue": "98", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "7.6", "ciUpperLimit": "14.0"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "1.5 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "10.2", "ciPctValue": "98", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "7.0", "ciUpperLimit": "13.4"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "2 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "11.2", "ciPctValue": "98", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "8.0", "ciUpperLimit": "14.4"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "3 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "11.5", "ciPctValue": "98", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "8.3", "ciUpperLimit": "14.7"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "4 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "9.7", "ciPctValue": "98", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "6.5", "ciUpperLimit": "12.8"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "6 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "10.4", "ciPctValue": "98", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "7.2", "ciUpperLimit": "13.5"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "12 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "7.3", "ciPctValue": "98", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "4.1", "ciUpperLimit": "10.4"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "24 hours postdose", "nonInferiorityType": "SUPERIORITY", "paramType": "Least Squares Mean Difference", "paramValue": "7.0", "ciPctValue": "98", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.8", "ciUpperLimit": "10.2"}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "timeFrame": "Treatment-emergent adverse events were collected from the start of IMP administration up to an average of 31 days", "description": "Safety Analysis Set included subjects who received at least 1 dose of IMP and had postdose safety data.", "eventGroups": [{"id": "EG000", "title": "OPC-61815 16 mg", "description": "OPC-61815 16 mg was intravenously administered once a week.", "deathsNumAffected": 0, "deathsNumAtRisk": 47, "seriousNumAffected": 0, "seriousNumAtRisk": 47, "otherNumAffected": 3, "otherNumAtRisk": 47}, {"id": "EG001", "title": "OPC-61815 32 mg", "description": "OPC-61815 32 mg was intravenously administered once a week.", "deathsNumAffected": 0, "deathsNumAtRisk": 47, "seriousNumAffected": 0, "seriousNumAtRisk": 47, "otherNumAffected": 5, "otherNumAtRisk": 47}, {"id": "EG002", "title": "Moxifloxacin", "description": "400 mg tablet was orally administrated once a week.", "deathsNumAffected": 0, "deathsNumAtRisk": 48, "seriousNumAffected": 0, "seriousNumAtRisk": 48, "otherNumAffected": 1, "otherNumAtRisk": 48}, {"id": "EG003", "title": "Placebo", "description": "Placebo was intravenously administered once a week.", "deathsNumAffected": 0, "deathsNumAtRisk": 47, "seriousNumAffected": 0, "seriousNumAtRisk": 47, "otherNumAffected": 2, "otherNumAtRisk": 47}], "otherEvents": [{"term": "Vessel puncture site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 47}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 47}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 48}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 47}]}, {"term": "Folliculitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 47}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 47}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 48}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 47}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 47}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 47}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 48}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 47}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 47}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 47}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 48}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 47}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 47}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 47}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 48}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 47}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 47}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 47}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 48}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 47}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Director of Clinical Trials", "organization": "Otsuka Pharmaceutical Co., LTD.", "email": "CL_OPCJ_RDA_Team@otsuka.jp", "phone": "+81-3-6361-7366"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2018-02-27", "uploadDate": "2021-03-11T23:36", "filename": "Prot_000.pdf", "size": 943378}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2018-09-25", "uploadDate": "2021-03-11T23:35", "filename": "SAP_001.pdf", "size": 439537}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Congestive Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077266", "term": "Moxifloxacin"}], "ancestors": [{"id": "D000000900", "term": "Anti-Bacterial Agents"}, {"id": "D000000890", "term": "Anti-Infective Agents"}, {"id": "D000059005", "term": "Topoisomerase II Inhibitors"}, {"id": "D000059003", "term": "Topoisomerase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000970", "term": "Antineoplastic Agents"}], "browseLeaves": [{"id": "M1722", "name": "Moxifloxacin", "asFound": "Beta", "relevance": "HIGH"}, {"id": "M266292", "name": "Norgestimate, ethinyl estradiol drug combination", "relevance": "LOW"}, {"id": "M4222", "name": "Anti-Bacterial Agents", "relevance": "LOW"}, {"id": "M4214", "name": "Anti-Infective Agents", "relevance": "LOW"}, {"id": "M29348", "name": "Topoisomerase Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "ANeo", "name": "Antineoplastic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Repr", "name": "Reproductive Control Agents"}]}}, "hasResults": true}